Bio2 Technologies' CLM Bioactive Scaffold receives FDA approval

Written by Anuja Vaidya | December 22, 2014 | Print  |

Bio2 Technologies received 510(k) clearance from the U.S. Food and Drug Administration for its CLM Bioactive Scaffold.

CLM is constructed from bioactive glass, a resorbable implantable material. Bio2 has successfully applied the proprietary CLM process technology to produce a rigid, osteoconductive material with an interconnected porous structure facilitating the ingrowth and remodeling of healthy bone.

 

Bio2 is focused on developing a number of CLM-constructed products designed for reconstructive surgery of the extremities.

More articles on devices:

Amedica's 2014 revenue to hit $22M to $24M — 6 things to know
Sonoma Orthopedic Products receives $12M in financing round
THINK Surgical's surgical system for THA receives FDA approval

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months